Are you in compliance?

Don't miss out! Sign up today for our weekly newsletters and stay abreast of important GRC-related information and news.


Status message

Start your free, no obligation 5-day trial to continue exploring with full access.

Daiichi Sankyo to Pay $39 Million for FCA Violations

Jaclyn Jaeger | January 19, 2015

Japanese pharmaceutical company Daiichi Sankyo this month agreed to pay $39 million to the government to resolve allegations that it violated the False Claims Act by paying kickbacks to induce physicians to prescribe Daiichi drugs.  

The Anti-Kickback Statute prohibits anyone from offering, paying, soliciting or receiving payment to induce referrals of items or services covered by federal health care programs, including Medicare and Medicaid. 

According to the complaint, Daiichi paid physicians kickbacks under the guise of speaker fees as part of Daiichi’s Physician Organization and Discussion programs (PODs) from 2005 to 2011. Some physicians in the POD program received kickbacks while “speaking” on duplicative topics over expensive Daiichi-paid dinners, or for simply speaking to their own staff members about Daiichi products in...

Read this single article for $49, or click the subscribe button below to review subscription options.

Enjoy unlimited access to thousands of articles, browse five years of digital magazines, qualify for reduced admission to events, and more.